Ironwood Pharmaceuticals (IRWD) EV to EBITDA (2010 - 2026)

Ironwood Pharmaceuticals has disclosed EV to EBITDA across 17 years of filings, most recently posting 7.77 for Q2 2026.

• In Q2 2026, EV to EBITDA rose 1361.9% year-over-year to 7.77; the TTM figure through Jun 2026 stood at 2.63 (up 701.2% YoY), while the FY2025 annual figure was 3.39, down 49.16% from the prior year.
• EV to EBITDA came in at 7.77 for Q2 2026 at Ironwood Pharmaceuticals, up from 4.92 in the prior quarter.
• In the past five years, EV to EBITDA ranged from a high of 114.61 in Q1 2024 to a low of 4.44 in Q1 2025.
• Average EV to EBITDA over 5 years is 23.64, with a median of 19.01 recorded in 2022.
• Year-over-year, EV to EBITDA tumbled 106.05% in 2023 and jumped 2837.04% in 2024.
• Over 5 years, EV to EBITDA stood at 18.3 in 2022, then jumped by 146.66% to 45.13 in 2023, then plunged by 56.3% to 19.72 in 2024, then soared by 148.87% to 49.09 in 2025, then plunged by 84.16% to 7.77 in 2026.
• Per Business Quant data, the three most recent EV to EBITDA figures were 7.77 in Q2 2026, 4.92 in Q1 2026, and 49.09 in Q4 2025.